Aarey Drugs & Pharmaceuticals Limited

Aarey Drugs to hold 36th AGM on Sep 30, 2026, for FY26 results and RPT approval

Aarey Drugs & Pharmaceuticals Limited will hold its 36th AGM on September 30, 2026, to approve FY26 financial results and related party transactions for FY27. E-voting is open from Sep 27-29, 2026, with a cut-off date of Sep 23, 2026. Related party transaction limits proposed include up to ₹45 Cr with Enam Organics India Ltd.

Aarey Drugs Announces Book Closure for 36th AGM from Sep 24-30

Aarey Drugs & Pharmaceuticals Limited will close its books for the 36th AGM from September 24 to September 30, 2026. This is a routine procedural notice for the meeting.

Aarey Drugs Board Approves 36th AGM Notice, Sets E-voting Cut-off Date

Aarey Drugs & Pharmaceuticals Limited's Board approved the notice for its 36th AGM, scheduled for September 30, 2026, via VC/OAVM. The Board also approved the Annual Report and set a cut-off date for e-voting, appointing Virendra G. Bhatt as scrutinizer.

Aarey Drugs Q1 FY27 Unaudited Results: Income ₹46.34 Crore, Net Profit ₹1.02 Crore

Aarey Drugs & Pharmaceuticals Limited reported unaudited financial results for Q1 FY27. Total income from operations was ₹46.34 crore. Net profit after tax stood at ₹1.02 crore. Basic and diluted EPS were ₹0.36. The Board approved the results on August 14, 2026.

Aarey Drugs Q1 FY27 Unaudited Results: Profit Declines to ₹1.02 Crore

Aarey Drugs & Pharmaceuticals Limited reported unaudited Q1 FY27 results with a profit of ₹1.02 crore, down from ₹1.37 crore year-on-year. Total income was ₹463.40 lakhs. The company also confirmed no deviation in the utilization of funds raised via preferential issue during the quarter. Trading window to reopen post-announcement.

Aarey Drugs Allots 25.2 Lakh Equity Shares on Warrant Conversion

Aarey Drugs & Pharmaceuticals Limited approved the allotment of 25,20,000 equity shares upon conversion of warrants. This conversion raised ₹12.06 crore. The company's issued and paid-up capital increased to ₹33.35 crore. 24,80,000 warrants remain outstanding.

Aarey Drugs & Pharma: Certificate under SEBI Depositories Regs for Q1 FY27

Aarey Drugs & Pharmaceuticals Limited received a certificate for the quarter ended June 30, 2026, under SEBI (Depositories and Participants) Regulations, 2018. The Registrar and Share Transfer Agent confirmed the processing of dematerialised securities.

Aarey Drugs Publishes Audited Financial Results for Q4FY26

Aarey Drugs & Pharmaceuticals Limited announced its audited standalone financial results for Q4FY26. Total income for the quarter was ₹18,904.29 lakh, with a profit of ₹155.74 lakh. For the full financial year, total income reached ₹47,836.61 lakh, and profit was ₹396.76 lakh. The Board approved these results on May 30, 2026.

Aarey Drugs Board Approves Audited Standalone Results for FY26, Declares Unmodified Audit Report

Aarey Drugs & Pharmaceuticals Limited's board meeting on May 30, 2026, approved audited standalone financial results for Q4 and FY26 ending March 31, 2026. An unmodified audit report was received. The company also reviewed its utilization of funds from a preferential issue. Total assets were ₹21,714.81 Lakh.

Aarey Drugs & Pharmaceuticals Clarifies Financial Results Mismatch

Aarey Drugs & Pharmaceuticals Limited submitted revised financial results for the quarter ended December 31, 2025, due to a clerical error causing a mismatch in PAT figures. The revised results were uploaded on April 11, 2026.

Aarey Drugs & Pharma Files SEBI Certificate for Q4FY26 Dematerialisation

Aarey Drugs & Pharmaceuticals Limited submitted a SEBI certificate for the quarter ended March 31, 2026. The certificate confirms dematerialisation processing by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.

Aarey Drugs & Pharmaceuticals: Trading Window Closed from April 1, 2026, for FY26 Audited Results

Aarey Drugs & Pharmaceuticals Limited will close its trading window from April 1, 2026. The closure is in anticipation of the declaration of audited financial results for the fourth quarter and financial year ended March 31, 2026. The trading window will reopen 48 hours after the results are announced.

Aarey Drugs & Pharma Publishes Q3 FY26 Unaudited Financial Results

Aarey Drugs & Pharmaceuticals Limited announced its unaudited financial results for Q3 FY26. Total income from operations for the quarter was ₹274.66 Lakhs, with a net profit before tax of ₹230.23 Lakhs. For the nine months ended December 31, 2025, total income was ₹(331.75) Lakhs and net profit before tax was ₹(452.10) Lakhs.

Aarey Drugs Fined ₹5,900 Each by BSE & NSE for Delayed Related Party Transaction Disclosure

Aarey Drugs & Pharmaceuticals Limited was fined ₹5,900 each by BSE and NSE for delayed submission of related party transactions for the period ending September 30, 2025. The company has paid the fine and assured that corrective measures are in place to prevent future non-compliance.

Aarey Drugs & Pharmaceuticals Ltd. Board Approves Unaudited Financial Results for Q3 FY26

Aarey Drugs & Pharmaceuticals Limited's Board of Directors approved the unaudited financial results for the quarter ended December 31, 2025. The board meeting was held on February 11, 2026.

Aarey Drugs Files SEBI Compliance Certificate for Q3 FY26

Aarey Drugs & Pharmaceuticals Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The filing confirms the processing of dematerialized securities by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.

Aarey Drugs & Pharmaceuticals: Trading Window Closed Jan 1, 2026, for Q3 Results

Aarey Drugs & Pharmaceuticals will close its trading window from January 1, 2026, until 48 hours after the declaration of Q3 FY26 unaudited financial results. The board meeting date for approving these results will be announced later.

Aarey Drugs & Pharmaceuticals announces Q2 FY26 unaudited financial results; strong consolidated growth observed

Aarey Drugs & Pharmaceuticals announced unaudited Q2 FY26 results. Standalone net profit declined, but consolidated net profit and income saw significant growth, boosting EPS.

Aarey Drugs & Pharmaceuticals Board Approves Q2 and H1 FY26 Unaudited Financial Results

Aarey Drugs & Pharmaceuticals Board approved Q2 and H1 FY26 unaudited financial results, showing a decline in revenue and net profit compared to the previous year.

Aarey Drugs files SEBI Reg. 74(5) Certificate for Quarter/Half Year Ended Sep 2025

Aarey Drugs submitted a Regulation 74(5) certificate for Q2/H1 FY26, confirming dematerialization process compliance for the period ended September 30, 2025, as per SEBI regulations.

Aarey Drugs & Pharmaceuticals Limited Shareholders Approve All Resolutions at 35th AGM

Aarey Drugs corrects FY25 Integrated Annual Report for typographical errors

Newspaper Publication of Notice of 35th AGM

Book Closure for 35th Annual General Meeting

Aarey Drugs Approves Board Report, AGM Date, Auditor Appointments

Aarey Drugs Board Approves AGM, Recommends Secretarial & Statutory Auditors for 5-Year Terms

Aarey Drugs Revised Audited Financial Results for Year Ended March 31, 2025